About Agenus (NASDAQ:AGEN)
Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company's discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company's vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:AGEN
CUSIP00847G70
Phone781-674-4400
Debt
Debt-to-Equity Ratio-1.88%
Current Ratio1.30%
Quick Ratio1.30%
Price-To-Earnings
Trailing P/E Ratio-3.06
Forward P/E Ratio-2.47
P/E GrowthN/A
Sales & Book Value
Annual Sales$42.88 million
Price / Sales8.99
Cash FlowN/A
Price / CashN/A
Book Value($0.74) per share
Price / Book-5.08
Profitability
EPS (Most Recent Fiscal Year)($1.23)
Net Income$-120,690,000.00
Net Margins-281.49%
Return on EquityN/A
Return on Assets-72.33%
Miscellaneous
Employees255
Outstanding Shares102,560,000
Agenus (NASDAQ:AGEN) Frequently Asked Questions
What is Agenus' stock symbol?
Agenus trades on the NASDAQ under the ticker symbol "AGEN."
How were Agenus' earnings last quarter?
Agenus Inc (NASDAQ:AGEN) issued its earnings results on Thursday, March, 15th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.28) by $0.07. The biotechnology company earned $8.30 million during the quarter, compared to the consensus estimate of $5.30 million. Agenus's revenue was up 48.2% compared to the same quarter last year. View Agenus' Earnings History.
When is Agenus' next earnings date?
What price target have analysts set for AGEN?
3 Wall Street analysts have issued 12-month target prices for Agenus' shares. Their predictions range from $5.00 to $7.00. On average, they anticipate Agenus' stock price to reach $6.3333 in the next year. View Analyst Ratings for Agenus.
Who are some of Agenus' key competitors?
Some companies that are related to Agenus include La Jolla Pharmaceutical (LJPC), Coherus BioSciences (CHRS), Novavax (NVAX), Jounce Therapeutics (JNCE), Voyager Therapeutics (VYGR), Fate Therapeutics (FATE), Heska (HSKA), Mesoblast (MESO), EntreMed (CASI), BioCryst Pharmaceuticals (BCRX), PDL Biopharma (PDLI), Vericel (VCEL), Nightstar Therapeutics (NITE), Idera Pharmaceuticals (IDRA), Solid Biosciences (SLDB), Cellular Biomedicine (CBMG), Adverum Biotechnologies (ADVM) and NantKwest (NK).
Who are Agenus' key executives?
Agenus' management team includes the folowing people:
- Garo H. Armen Ph.D., Chairman of the Board, Chief Executive Officer, Founder (Age 64)
- Christine M. Klaskin, Vice President - Finance (Age 51)
- Karen Higgins Valentine, General Counsel, Chief Legal Officer (Age 45)
- Ozer Baysal, Chief Commercial Officer, Head of HR (Age 61)
- Brian Corvese, Independent Director (Age 59)
- Wadih Jordan, Independent Director (Age 82)
- Shalini Sharp, Independent Director (Age 42)
- Ulf Wiinberg, Independent Director (Age 58)
- Timothy R. Wright, Independent Director (Age 59)
Has Agenus been receiving favorable news coverage?
Press coverage about AGEN stock has been trending positive this week, Accern Sentiment Analysis reports. Accern rates the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Agenus earned a news impact score of 0.36 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 48.19 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
How do I buy shares of Agenus?
Shares of AGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Agenus' stock price today?
One share of AGEN stock can currently be purchased for approximately $3.76.
How big of a company is Agenus?
Agenus has a market capitalization of $419.46 million and generates $42.88 million in revenue each year. The biotechnology company earns $-120,690,000.00 in net income (profit) each year or ($1.23) on an earnings per share basis. Agenus employs 255 workers across the globe.
How can I contact Agenus?
Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-674-4400 or via email at [email protected]
MarketBeat Community Rating for Agenus (AGEN)
MarketBeat's community ratings are surveys of what our community members think about Agenus and other stocks. Vote "Outperform" if you believe AGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Agenus (NASDAQ:AGEN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Agenus in the last 12 months. Their average twelve-month price target is $6.3333, suggesting that the stock has a possible upside of 68.44%. The high price target for AGEN is $7.00 and the low price target for AGEN is $5.00. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.67 | 2.67 | 2.67 | 2.75 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $6.3333 | $6.3333 | $6.3333 | $6.3333 |
| Price Target Upside: | 68.44% upside | 57.55% upside | 57.55% upside | 57.55% upside |
Agenus (NASDAQ:AGEN) Consensus Price Target History
Agenus (NASDAQ:AGEN) Analyst Ratings History
Show:
(Data available from 4/20/2016 forward)
Agenus (NASDAQ:AGEN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Agenus (NASDAQ AGEN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 7.60%
Institutional Ownership Percentage: 36.46%
Agenus (NASDAQ AGEN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/12/2017 | Alex Duncan | CTO | Sell | 6,546 | $3.46 | $22,649.16 | 27,572 |  |
| 12/12/2017 | Christine M Klaskin | VP | Sell | 5,610 | $3.46 | $19,410.60 | 69,943 | |
| 12/12/2017 | Karen Valentine | Insider | Sell | 8,358 | $3.46 | $28,918.68 | 109,879 | |
| 10/30/2017 | Garo H Armen | CEO | Buy | 100,000 | $3.55 | $355,000.00 | | |
| 4/12/2017 | Garo H Armen | CEO | Buy | 100,000 | $3.35 | $335,000.00 | 1,389,021 | |
| 2/14/2017 | Corp Incyte | Major Shareholder | Buy | 10,000,000 | $6.00 | $60,000,000.00 | 17,763,968 | |
| 9/6/2016 | Ulf Wiinberg | Director | Buy | 30,000 | $6.29 | $188,700.00 | 30,000 | |
| 5/9/2016 | Garo H Armen | CEO | Buy | 100,000 | $3.18 | $318,000.00 | 1,346,026 | |
| 5/5/2016 | Ozer Baysal | Insider | Buy | 2,250 | $3.10 | $6,975.00 | 33,538 | |
| 3/7/2016 | Garo H Armen | CEO | Buy | 200,000 | $4.03 | $806,000.00 | 1,251,228 | |
| 12/29/2015 | Garo H. Armen | CEO | Sell | 219,576 | $4.59 | $1,007,853.84 | 1,051,228 | |
| 12/28/2015 | Garo H. Armen | CEO | Sell | 134,352 | $4.60 | $618,019.20 | 1,051,228 | |
| 9/25/2015 | Charles Evan Ballantyne | CFO | Buy | 10,000 | $5.05 | $50,500.00 | 10,000 | |
| 9/25/2015 | Garo H Armen | CEO | Buy | 100,000 | $5.03 | $503,000.00 | 1,409,607 | |
| 4/29/2015 | Shahzad Malik | Director | Sell | 1,107,377 | $7.11 | $7,873,450.47 | | |
| 1/9/2015 | Qvt Associates Gp Llc | Major Shareholder | Sell | 2,343,630 | $5.31 | $12,444,675.30 | | |
| 1/23/2014 | Karen Valentine | VP | Sell | 2,850 | $3.50 | $9,975.00 | 51,534 | |
(Data available from 1/1/2013 forward)
Agenus (NASDAQ AGEN) News Headlines
| Source: |
|
Agenus (NASDAQ:AGEN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Agenus (NASDAQ:AGEN) Income Statement, Balance Sheet and Cash Flow Statement
Agenus (NASDAQ AGEN) Stock Chart for Friday, April, 20, 2018
Loading chart…
